Skip to main content

Table 2 Univariate survival analyses according to primary tumor factors and DTC/CTC status

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

 

DFSª (n= 211)

BCSSb (n= 236)

OS (n= 236)c

 

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

DTC status

         

   BM1-pos vs. BM1-neg

1.1

0.7-1.8

0.602

1.0

0.7-1.7

0.857

1.1

0.7-1.7

0.671

   BM2-pos vs. BM2-neg

1.3

0.6-3.1

0.480

1.2

0.5-2.9

0.715

1.2

0.5-2.9

0.715

   BM3-pos vs. BM3-neg

2.3

1.3-3.9

0.003

3.0d

1.8-5.2d

< 0.001d

2.8e

1.7-4.7e

< 0.001e

cN status (vs. cN0)

  

0.001

  

< 0.001

  

< 0.001

   cN1

2.1

1.3-3.3

0.001

2.3

1.5-3.6

< 0.001

2.2

1.4-3.4

< 0.001

   cN 2-4

2.5

1.4-4.5

0.003

3.0

1.7-5.3

< 0.001

2.8

1.6-4.8

< 0.001

Hormone receptor status

         

   PgR-pos vs. PgR-neg

1.6

1.0-2.3

0.034

2.0

1.4-2.8

< 0.001

1.8

1.3-2.6

0.001

   ER-pos vs. ER-neg

1.7

1.2-2.6

0.007

1.9

1.3-2.6

< 0.001

1.8

1.3-2.5

0.001

Histological grade

         

   Grade 3 vs. grade 1-2

1.4

1.1-1.7

0.003

1.4

1.2-1.7

0.001

2.0

1.3-3.0

0.001

cT status

         

   cT4 vs. cTX-3

1.1

0.7-1.9

0.584

1.3

0.8-2.0

0.226

1.4

0.9-2.1

0.151

CTC status

         

   PB1-pos vs. PB1-neg

2.0

0.8-4.8

0.146

2.2f

1.0-4.8f

0.046f

2.1g

1.0-4.6g

0.057g

   PB2 pos vs. PB2-neg

1.8

0.2-13.5

0.551

1.6

0.2-12.0

0.631

1.6

0.2-12.0

0.631

   PB3-pos vs. PB3-neg

1.6

0.5-5.1

0.434

2.0

0.6-6.4

0.258

1.8

0.6-5.9

0.318

Clinical response

         

   No CR vs. CR

1.2

0.5-2.9

0.737

1.2

0.5-3.0

0.651

1.2

0.5, 2.9

0.727

  1. ªDisease-free survival (DFS) only for M0 patients.
  2. bBreast cancer specific survival (BCSS) for all patients.
  3. cOverall survival (OS) for all patients.
  4. dBCSS according to bone marrow aspiration at BM3 analyzed for M0 patients only: hazard ratio (HR) 2.6, 95% CI 1.4-4.6, P = 0.002.
  5. eOS according to BM3 status analyzed for stage M0 patients only: HR 2.4, 95% CI 1.4-4.2, P = 0.003.
  6. fBCSS according to peripheral blood sampling at PB1 analyzed for stage M0 patients only: HR 2.1, 95% CI 0.8-5.1, P = .116.
  7. gOS according to PB1 status analyzed for stage M0 patients only: HR 2.0, 95% CI 0.8-4.9, P = 0.142.
  8. BM1, BM2 and BM3: bone marrow aspiration pre-treatment, at surgery, and 12 months after start of neoadjuvant treatment respectively.
  9. cT: clinical tumor status; cN: clinical lymph node status; M0: no metastases present; DTC: disseminated tumor cells; CTC: circulating tumor cells; CR: complete response.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us